Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Oct;113(2):576-80.
doi: 10.1111/j.1476-5381.1994.tb17028.x.

The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats

Affiliations

The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats

D J Otter et al. Br J Pharmacol. 1994 Oct.

Abstract

1. The responses of rat isolated aortae to vasoconstrictor and vasodilator agents have been studied in 14-day streptozotocin-diabetic rats. The effects of treatment with the aldose reductase inhibitor, ponalrestat, on these responses have also been investigated. 2. Maximum contractile responses and aortic sensitivity to phenylephrine were significantly enhanced in 14-day diabetic aortae. 3. In contrast, endothelium-dependent relaxations to carbachol were depressed in diabetic rats, whilst endothelium-independent relaxations to forskolin and sodium nitroprusside were unchanged. 4. Pretreatment with ponalrestat (25 mg kg-1, daily) prevented both the enhanced maximum contractile responses to phenylephrine and the depressed endothelium-dependent relaxations to carbachol in aortae from 14-day diabetic rats. Ponalrestat however, had no effect on the reduced phenylephrine EC50 values observed in tissues from diabetic animals. 5. It is concluded that ponalrestat prevents the depression of endothelium-dependent aortic relaxations induced by diabetes of 14 days duration, suggesting that the polyol pathway is involved in these vascular changes. Ponalrestat does not prevent the increase in aortic sensitivity to alpha 1-adrenoceptor agonists.

PubMed Disclaimer

References

    1. N Engl J Med. 1973 Apr 19;288(16):831-6 - PubMed
    1. Br J Pharmacol. 1994 Jan;111(1):42-8 - PubMed
    1. Am J Med. 1979 Nov;67(5):779-84 - PubMed
    1. Am J Physiol. 1980 Dec;239(6):E412-21 - PubMed
    1. Diabetes. 1985 Jan;34(1):15-21 - PubMed

MeSH terms

LinkOut - more resources